Pacific Biosciences reported Q4 revenue of $44.6 million, a 14% year‑over‑year increase that beat Street estimates, and full‑year 2025 revenue of $160.0 million. The company flagged record consumables revenue and growth in clinical market adoption, shipped multiple Revio and Vega instruments, and emphasized plans for SPRQ‑Nx to lower sequencing costs. Separately, PacBio announced a collaboration with Genetic Alliance to integrate long‑read sequencing into the iHope rare‑disease program, expanding access to comprehensive genomic diagnostics for children with suspected genetic conditions. Management pointed to strengthened balance-sheet positioning post‑short‑read asset sale and reiterated long‑read platforms as the core growth driver.